Concepedia

Karin Amundson

KA

Statistics

Publications

6

Citations

1.1K

H-Index

6

Active since

2008

Affiliations

Pfizer (United States)(Current)

University of California, Los Angeles

Karin Amundson is an author at Pfizer (United States) specializing in oncology, pharmacology, and molecular oncology.

Publications per year

2008–2025

6

Publications

6

Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3

Dana D. Hu‐Lowe, Helen Y. Zou, Maren L. Grazzini et al. · Clinical Cancer Research · 2008 · 628 citations

, , +17

Design and Selection of Toca 511 for Clinical Use: Modified Retroviral Replicating Vector With Improved Stability and Gene Expression

Omar D. Perez, Christopher R. Logg, Kei Hiraoka et al. · Molecular Therapy · 2012 · 138 citations · Full text

, , +13

Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector

Derek Ostertag, Karin Amundson, F. Lopez Espinoza et al. · Neuro-Oncology · 2011 · 137 citations · Full text

, , +12

Targeting Activin Receptor-Like Kinase 1 Inhibits Angiogenesis and Tumorigenesis through a Mechanism of Action Complementary to Anti-VEGF Therapies

Dana D. Hu‐Lowe, Enhong Chen, Lianglin Zhang et al. · Cancer Research · 2011 · 133 citations · Full text

, , +17

Dual Functional Monoclonal Antibody PF-04605412 Targets Integrin α5β1 and Elicits Potent Antibody-Dependent Cellular Cytotoxicity

Gang Li, Lianglin Zhang, Enhong Chen et al. · Cancer Research · 2010 · 25 citations · Full text

, , +17

1–5 of 6